Skip to main content
SpringerLink
Log in

Therapy of B-cell Lymphoproliferative Disorders

  • Chapter
  • First Online:
Neoplastic Hematopathology

Part of the book series: Contemporary Hematology ((CH))

Abstract/Scope of Chapter

The majority (>80%) of both aggressive and indolent variants of NHL are of B-cell origin, and their treatment is discussed in this chapter. Therapeutic options range from close observation with intervention only with disease progression to treatment at diagnosis with intensive multiagent regimens. With the development of new chemotherapeutic regimens and advances in supportive care, improved outcomes are becoming apparent. The introduction of antibody immunotherapy, immunomodulatory agents, and small molecules that target lymphoma signaling pathways are leading to further customized therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. Ca Cancer J Clin 2008;58:71-96.

    Article  PubMed  Google Scholar 

  2. Swerdlow S, Campo E, Harris N, eds. World health organization classification of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyon, 2008.

    Google Scholar 

  3. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6387-93.

    Article  PubMed  CAS  Google Scholar 

  4. Swenson W, Wooldridge J, Lynch C, Forman-Hoffman V, Chrischilles E, Link B. Improved survival of follicular lymphoma patients in the united states. J Clin Oncol 2005;23:5019-26.

    Article  PubMed  Google Scholar 

  5. Gascoyne R. Establishing the diagnosis of lymphoma: from initial biopsy to clinical staging. Oncology 1998;10:11-6.

    Google Scholar 

  6. Lister TA, Crowther D, Sutcliffe SB. et al "Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting". J Clin Oncol 1989;11:1630-6.

    Google Scholar 

  7. Cheson B, Pfistner B, Juweid M, et al. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 2007;25:579-86.

    Article  PubMed  Google Scholar 

  8. Cheson B, Leonard J. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 2008;359:613-26.

    Article  PubMed  CAS  Google Scholar 

  9. 2008/2009 National Comprehensive Cancer Center Guidelines. (Accessed March 12, 2009, at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

  10. Coiffier B, Altman A, Pui C, Younes A, Cairo M. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review. J Clin Oncol 2008;16:2767-78.

    Article  Google Scholar 

  11. Juweid M, Stroobants S, Hoekstra O, et al. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8.

    Article  PubMed  Google Scholar 

  12. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540-5.

    Article  PubMed  CAS  Google Scholar 

  13. Khouri I, Saliba R, Hosing C, et al Autologous stem cell vs nonmyeloablative allogeneic transplantation after high-dose rituximab-containing conditioning regimens for relapsed chemosensitive follicular lymphoma. Blood 2005; 106:19a, (abstr 48).

    Google Scholar 

  14. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-84.

    Article  PubMed  CAS  Google Scholar 

  15. Johnson P. New targets for lymphoma treatment. Ann Oncol 2008;19 Suppl 4;56-9.

    Google Scholar 

  16. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423.

    Google Scholar 

  17. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002-6.

    Article  PubMed  CAS  Google Scholar 

  18. Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Hemae 2008;143:607-21.

    Article  CAS  Google Scholar 

  19. Perkins A, Friedberg J. Burkitt lymphoma in adults. Hematology 2008;1:341-8.

    Article  Google Scholar 

  20. Anderson V, Perry C. Fludarabine: A review of its use in non-Hodgkin’s lymphoma. Drugs. 2007;67:1633-55.

    Article  PubMed  CAS  Google Scholar 

  21. Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995;6:609-11.

    PubMed  CAS  Google Scholar 

  22. Samaniego F, Fanale M, et al. Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lymphoma without Prolonged Myelosuppression. Blood 2008;112:835.

    Google Scholar 

  23. Zinzani P. Salvage Chemotherapy in Follicular Non-Hodgkin’s Lymphoma: Focus on Tolerability. Clin Lymph & Myeloma 2006;7:115-24.

    Article  CAS  Google Scholar 

  24. Abramson J, Shipp M. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164-74.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Lymphoma & Myeloma, M. D. Anderson Cancer Center, The University of Texas, Houston, TX, USA

    Nathan Fowler & Peter McLaughlin

  2. Pharmacy Clinical Programs, M. D. Anderson Cancer Center, The University of Texas, Houston, TX, USA

    Sandra Horowitz

Authors
  1. Nathan Fowler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra Horowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter McLaughlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, The University of Texas, Holcombe Blvd. 1515 , Houston, 77030, U.S.A.

    Dan Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Fowler, N., Horowitz, S., McLaughlin, P. (2010). Therapy of B-cell Lymphoproliferative Disorders. In: Jones, D. (eds) Neoplastic Hematopathology. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-384-8_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-384-8_18

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-383-1

  • Online ISBN: 978-1-60761-384-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation